Development
Predictive Oncology Inc.
POAI
$0.9386
-$0.0114-1.20%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 45.91% | 104.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 45.91% | 104.29% | |||
| Cost of Revenue | -33.10% | 33.06% | |||
| Gross Profit | 84.11% | 175.71% | |||
| SG&A Expenses | -8.83% | 15.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.74% | 15.70% | |||
| Operating Income | 16.92% | -9.56% | |||
| Income Before Tax | 19.37% | -14.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.37% | -14.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.37% | -14.66% | |||
| EBIT | 16.92% | -9.56% | |||
| EBITDA | 17.29% | -12.06% | |||
| EPS Basic | 20.07% | -13.85% | |||
| Normalized Basic EPS | 16.61% | -9.11% | |||
| EPS Diluted | 20.07% | -13.85% | |||
| Normalized Diluted EPS | 16.61% | -9.11% | |||
| Average Basic Shares Outstanding | 0.87% | 0.72% | |||
| Average Diluted Shares Outstanding | 0.87% | 0.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||